When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. ALK inhibitor - Wikipedia

   en.wikipedia.org/wiki/ALK_inhibitor

   As such, Novartis' ceritinib was approved by the FDA in April 2014 for treatment of NSCLC. [ 2 ] [ 11 ] It provided good brain penetrance and a significant progression-free survival benefit against chemotherapy in the first line as demonstrated in the ASCEND-4 trial.

3. Treatment of lung cancer - Wikipedia

   en.wikipedia.org/wiki/Treatment_of_lung_cancer

   In 2019, the FDA approved pembrolizumab for the first-line treatment of people with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLC. people' tumors must have no EGFR or ALK genomic aberrations and express PD-L1 (Tumor Proportion Score [TPS] >1% ...

4. Lung cancer - Wikipedia

   en.wikipedia.org/wiki/Lung_cancer

   Lung cancer is the most diagnosed and deadliest cancer worldwide, with 2.2 million cases in 2020 resulting in 1.8 million deaths. [3] Lung cancer is rare in those younger than 40; the average age at diagnosis is 70 years, and the average age at death 72. [2] Incidence and outcomes vary widely across the world, depending on patterns of tobacco use.

5. Non-small-cell lung cancer - Wikipedia

   en.wikipedia.org/wiki/Non-small-cell_lung_cancer

   The main treatment arms of phase 3 clinical trials providing immunotherapy in the first line for patients with non-small cell lung cancer. [60] Non-small cell lung cancer (NSCLC) cells expressing programmed death-ligand 1 (PD-L1) could interact with programmed death receptor 1 (PD-1) expressed on the surface of T cells, and result in decreased ...

6. Combined small-cell lung carcinoma - Wikipedia

   en.wikipedia.org/wiki/Combined_small-cell_lung...

   Combined small cell lung carcinoma (or c-SCLC) is a form of multiphasic lung cancer that is diagnosed by a pathologist when a malignant tumor, arising from transformed cells originating in lung tissue, contains a component of small cell lung carcinoma (SCLC) mixed with one or more components of any histological variant of non-small cell lung carcinoma (NSCLC) in any relative proportion.

7. Small-cell carcinoma - Wikipedia

   en.wikipedia.org/wiki/Small-cell_carcinoma

   Small-cell lung carcinoma (SCLC) has long been divided into two clinicopathological stages, termed limited stage (LS) and extensive stage (ES). [8] The stage is generally determined by the presence or absence of metastases, whether or not the tumor appears limited to the thorax, and whether or not the entire tumor burden within the chest can feasibly be encompassed within a single radiotherapy ...